On April 1, 2019 AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, reported that it will present at the H.C. Wainwright Global Life Sciences Conference in London, UK, taking place April 7 – 9, 2019 (Press release, AC Immune, APR 1, 2019, View Source [SID1234534830]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Prof. Andrea Pfeifer, Ph.D., CEO of AC Immune SA will present an update on AC Immune’s broad clinical and preclinical pipeline of therapeutic and diagnostic candidates to treat neurodegenerative diseases associated with misfolded proteins. The Company’s pipeline features nine therapeutic and three diagnostic product candidates, with five currently in clinical trials and has collaborations with major pharmaceutical companies including Roche/Genentech, Eli Lilly and Janssen.

AC Immune utilizes two proprietary discovery platforms, SupraAntigen and Morphomer, to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose, prevent and modify neurodegenerative diseases. These platforms have been validated through collaborations with major pharmaceutical companies, most recently a transformative agreement with Lilly for Tau Morphomer small molecules in Alzheimer’s disease and other Tau-related neurodegenerative diseases, with a total deal value of approx. CHF 1.8 billion.

H.C. Wainwright Global Life Sciences Conference
Date: April 9, 2019 | 1:30 – 1:50pm BST
Presenter: Prof. Andrea Pfeifer, CEO, AC Immune